ライフサイエンスコーパス: kidney function

1 istics, comorbidities, albumin, and residual kidney function).

2 nephropathy, whereas CB1R blockade improves kidney function.

3 ect kidney's filtration barrier and preserve kidney function.

4 tion and regression, and progressive loss of kidney function.

5 ejections, infections, treatment failure and kidney function.

6 lead to progressive fibrosis and decline in kidney function.

7 arding the impact of higher-protein diets on kidney function.

8 al adiposity, with no apparent impairment of kidney function.

9 igher rates among those with lower levels of kidney function.

10 y be alternative or complementary markers of kidney function.

11 , increased arterial stiffness, or decreased kidney function.

12 tween exposure and hypertension and impaired kidney function.

13 unction may provide an important estimate of kidney function.

14 of 0-1, and adequate bone marrow, liver, and kidney function.

15 s and inflammation and associated with worse kidney function.

16 ransport, TOR signalling, and osteoclast and kidney function.

17 risk is generalizable to patients with poor kidney function.

18 into complex structures that replicate human kidney function.

19 t of cystatin C, a non-creatinine measure of kidney function.

20 cipants to identify epigenetic signatures of kidney function.

21 ic ADMA reduction may even be deleterious to kidney function.

22 on, gene expression patterns, DSA levels, or kidney function.

23 informative; or, in the context of impaired kidney function.

24 unction, but not in participants with normal kidney function.

25 ioperative cTnT values for patients with low kidney function.

26 intake during pregnancy influences childhood kidney function.

27 ed glomerular filtration rate (eGFR) defined kidney function.

28 safety profile of R-ED, especially regarding kidney function.

29 s, but it is insufficient to maintain normal kidney function.

30 engths were not consistently associated with kidney function.

31 rmin in patients with significantly impaired kidney function.

32 ches aimed at normalizing the GBM to prolong kidney function.

33 ry disease severity in patients with reduced kidney function.

34 site in the terminal exon) is protective for kidney function.

35 ix accumulation, organ scarring, and loss of kidney function.

36 deleterious "on target" effect on liver and kidney function.

37 umulation of renal cysts eventually destroys kidney function.

38 orrelating these changes with future loss of kidney function.

39 position and central hemodynamics as well as kidney function.

40 its concentration in plasma is diagnostic of kidney function.

41 ation of nephrons in situ to restore failing kidney function.

42 poor renal outcomes in patients with normal kidney function.

43 non-coding genomic regions, associated with kidney function.

44 y associated with a lower risk of decline in kidney function.

45 SCs did not decrease the time to recovery of kidney function.

46 ovascular disease among patients with normal kidney function.

47 rtality and recipients who may regain native kidney function.

48 ovascular disease in populations with normal kidney function.

49 kedly attenuated cyst formation and restored kidney function.

50 re accurate predictors of recovery of native kidney function.

51 between soluble klotho levels and change in kidney function.

52 of annual deaths in individuals with normal kidney function.

53 se oligonucleotides and improved post-injury kidney function.

54 nor allele frequency >5% are associated with kidney function.

55 lating GDF-15 are associated with decline in kidney function.

56 dysfunction, myocyte injury and stress, and kidney function.

57 hagic cystitis (present/absent), and data on kidney function.

58 e samples, without compromising auditory and kidney functions.

59 pH maintenance, as well as other specialised kidney functions.

60 ates kidney damage and fibrosis and improves kidney functions.

61 were younger (59 vs. 67 years), had reduced kidney function (31% vs. 24%), and had peripheral vascul

62 n using Pepstatin A led to an improvement in kidney function, a reduction in apoptosis and a decrease

63 in a significant improvement in survival and kidney function, a reduction of apoptosis, improved hist

64 3-2.21), a 15% higher incidence of decreased kidney function (adjusted hazard ratio = 1.15, 95% CI 1.

65 mpensatory hypertrophy (RCH) restores normal kidney function after disease or loss of kidney tissue a

66 Primary end points were improved kidney function after rejection treatment and transplant

67 s of young patients with ADPKD and preserved kidney function already had higher levels of complement,

68 = 9,192) 30-65 years old and in relation to kidney function among adults > 20 years old (n = 29,499)

69 of intensive blood pressure (BP) lowering on kidney function among individuals with established cereb

70 identify a novel pathway involved in loss of kidney function among patients with CKD.

71 nt ESRD independent of the baseline level of kidney function and a number of other risk factors.

72 association of BMI with progressive loss of kidney function and all-cause mortality in US veterans.

73 vascular events but heterogeneous effects on kidney function and BP.

74 -scores indicate potential causal effects of kidney function and by lesser extent triglycerides on ap

75 lite concentrations may result from impaired kidney function and can be used to estimate filtration (

76 cerebral perfusion, the association between kidney function and cerebral blood flow has yet to be de

77 We examined the association between kidney function and change in cognitive function in 3,90

78 marker for biological processes that affect kidney function and CKD in humans.

79 esign Mendelian randomization studies around kidney function and disease.

80 l epithelial cells and it plays key roles in kidney function and disease.

81 a critical role for sialosides in liver and kidney function and document the feasibility of pharmaco

82 Impaired kidney function and earlier menopause were associated wi

83 nic kidney disorders by returning endogenous kidney function and enabling patients to cease dialysis.

84 mones, FGF23 and osteocalcin, which regulate kidney function and glucose homeostasis, respectively.

85 nced stages of kidney disease independent of kidney function and glycemia.

86 old or male animals had more severe loss in kidney function and higher mortality rates than young or

87 vidence of association (p < 5 x 10(-8)) with kidney function and highlighted that allelic effects on

88 mans, these mice exhibited severely impaired kidney function and hypertension.

89 s in animals with Alport Syndrome, enhancing kidney function and improving survival.

90 The mediators of abnormal kidney function and increased blood pressure during deve

91 h serum retinol as well as the importance of kidney function and inflammation in this regard.

92 y everolimus but not R507, adversely altered kidney function and lipid profiles.

93 tionships with known susceptibility loci for kidney function and lipids.

94 n vivo inhibition of miR-182 by ASO improved kidney function and morphology after AKI.

95 ctional analog CCL8 and its receptor CCR8 on kidney function and morphology.

96 FR and albumin-to-creatinine ratio to assess kidney function and performed phase-contrast magnetic re

97 esults show the role of IgG glycosylation in kidney function and provide novel insight into the patho

98 dure, the patient maintains normal liver and kidney function and refers significant improvement in qu

99 lymorphisms are associated with variation in kidney function and related disease risk, but the relati

100 f early posttransplantation HRQoL along with kidney function and reported side effects because of the

101 ow promise for providing unique insight into kidney function and severity of fibrosis.

102 to evaluate the association between level of kidney function and subsequent cancer risk.

103 Our findings clarify the role of pendrin in kidney function and suggest pendrin inhibition as a nove

104 To assess the outcome of kidney function and survival of patients with type-1 HRS

105 ine whether the association between impaired kidney function and venous thrombosis can be explained b

106 explaining the association between impaired kidney function and venous thrombosis have not been iden

107 to <80 years, and >/=80 years) with loss of kidney function and with all-cause mortality in logistic

108 socioeconomic and medical data (comorbidity, kidney function) and completed the end-stage renal disea

109 lomerular filtration rate (eGFR, a marker of kidney function) and serum PFOA concentration were measu

110 rculatory pressure, proinflammatory markers, kidney function, and adiposity measures, in adults ages

111 ant enrichment in rheumatoid arthritis (RA), kidney function, and adult height (P < 0.05/18 = 0.0028,

112 Education, kidney function, and comorbidity also increased the risk

113 ors, body mass index, diabetes, aspirin use, kidney function, and coronary artery calcium score.

114 Patients had good bone marrow, liver and kidney function, and good performance status (Eastern Co

115 compared with MAG3-SRF, postoperation donor kidney function, and graft function.

116 ology of renal failure, may predict post-LAT kidney function, and may be helpful in kidney allocation

117 pitalization for HF, independent of level of kidney function, and other known HF risk factors.

118 igher mortality risk, incidence of decreased kidney function, and progressive loss of kidney function

119 isease, cardiovascular disease risk factors, kidney function, and serum hemoglobin.

120 up (n=14) included subjects matched for age, kidney function, and stenosis severity.

121 ns substantially increase with decrements in kidney function, and this effect is reversed by renal tr

122 levated suPAR levels in patients with normal kidney function are associated with future decline in th

123 Older adults with lower kidney function are at higher risk of worsening cognitiv

124 vious studies, earlier menopause and reduced kidney function are the causes rather than the results o

125 ral Pilot Registry (EORP-AF), in relation to kidney function, as assessed by glomerular filtration ra

126 Impaired kidney function, as measured by reduced estimated glomer

127 orescence imaging in preclinical noninvasive kidney function assessments.

128 Our findings highlight kidney function associated epigenetic variation.

129 two large, unrelated cohorts that decline in kidney function associated with APOL1 risk variants was

130 , our study provides a comprehensive list of kidney function-associated metabolites and highlights po

131 Six patients (15%) did not recover kidney function at 1 month and RRT at time of LT was the

132 need for dialysis, or persistent decline in kidney function at 90 days or for the prevention of cont

133 e of empagliflozin in patients with impaired kidney function at baseline was similar to that reported

134 y cadmium(UCd) and hypertension and impaired kidney function at low exposure levels (UCd: GM 1.3 mug/

135 oval of the influence of the renal nerves on kidney function attenuates renal neprilysin activity, au

136 atalog, we conducted a GWAS meta-analysis of kidney function based on the estimated glomerular filtra

137 Kidney function before PTA is a strong independent predi

138 all-cause and cardiovascular mortality, RRT, kidney function, BP, and adverse events.

139 of volatile anesthetics and their effect on kidney function, briefly review the studies on volatile

140 isk of incident ESRD independent of baseline kidney function but not independent of glycemia.

141 r of glomeruli is a fundamental parameter of kidney function but very difficult to determine using st

142 CKD is the gradual, asymptomatic loss of kidney function, but current tests only identify CKD whe

143 cal end points in participants with impaired kidney function, but not in participants with normal kid

144 in diabetic individuals with well preserved kidney function, but not in those with progressive disea

145 been considered the gold standard measure of kidney function, but recent studies have shown that mGFR

146 d by 55% with a corresponding improvement in kidney function by 88% in macrophage CD36-deficient mice

147 itrate, markers of endothelial dysfunction), kidney function by Chronic Kidney Disease Epidemiology C

148 idney injury (AKI) is an abrupt reduction in kidney function caused by different pathological process

149 syndrome characterized by a rapid decline in kidney function caused by ischemic or toxic injury to re

150 idney transplantation; (b) association among kidney function (chronic kidney disease stage), HRQoL, a

151 glycated albumin), and a latent variable for kidney function (creatinine, cystatin C, beta2-microglob

152 , nutritional factors, clinical factors, and kidney function/damage markers and accounting for interv

153 tions of APOL1 with incident albuminuria and kidney function decline among 3030 young adults with pre

154 HIV RNA suppression mitigates APOL1-related kidney function decline among African Americans enrolled

155 Patient and graft survival, rate of kidney function decline and patient reported symptoms we

156 tients (24%) in the lower BP group had rapid kidney function decline compared with 247 (19%) in the h

157 s in the United States, is a risk factor for kidney function decline in populations with CKD.

158 However, its role in kidney function decline in the general population is unk

159 Rapid kidney function decline was not associated with increase

160 assessed associations of both treatment and kidney function decline with stroke, major vascular even

161 ssociated with a greater likelihood of rapid kidney function decline.

162 xtent periodontal disease is associated with kidney function decline.

163 (3) end-stage renal disease, and (4) rate of kidney function decline.

164 ADMA metabolism protects against progressive kidney function decline.

165 nd is associated with clinically significant kidney function decline.

166 k genotype experience an accelerated rate of kidney function decline; HIV suppression with antiretrov

167 load (DAL) improves kidney injury and slows kidney function decline; however, the relationship betwe

168 ) is a toxin that accumulates in plasma when kidney function declines and contributes to the progress

169 of 3,376,187 veterans had a rapid decline in kidney function (decrease in slope of >5 mL/min per 1.73

170 primary outcome was the time to recovery of kidney function defined as return of postintervention cr

171 -cause mortality, (2) incidence of decreased kidney function (defined as eGFR <60 mL/min/1.73 m(2) an

172 GWAS meta-analysis results was performed on kidney function (defined by eGFR), HDL-cholesterol and t

173 African American participants with preserved kidney function (defined by estimated glomerular filtrat

174 f nonrenal solid organs, an acute decline in kidney function develops in the majority of patients.

175 initiate dialysis was based only on level of kidney function did not change over time.

176 earable probes is key to studying unilateral kidney function diseases, but such imaging is highly cha

177 ents with normal or near-normal preoperative kidney function (eGFR>/=60 ml/min per 1.73 m(2)), partia

178 pertension was mainly attributed to impaired kidney function (eGFR: 30%; urinary albumin: 5%) but not

179 r more information and validated measures of kidney function especially in the context of the growing

180 virus can reactivate but rarely compromises kidney function except in renal grafts, where it causes

181 genes and critical pathways associated with kidney function for future analysis.

182 sel patency alone is insufficient to recover kidney function for most subjects.

183 Moreover, the relationship between HRQoL and kidney function has never been investigated in kidney tr

184 ctomy versus radical nephrectomy to preserve kidney function has not been well established.

185 in-function studies of TRPC5 with respect to kidney function have not been reported.

186 nity-based study comprising a broad range of kidney function, higher baseline fibroblast growth facto

187 splanted CKD patients with similar levels of kidney function impairment and progressive and/or immuno

188 plication of MR-MEGA to trans-ethnic GWAS of kidney function in 71,461 individuals indicates stronger

189 , human SHROOM3 variants can induce impaired kidney function in animal models.

190 serum creatinine concentration overestimate kidney function in cirrhosis, leading to significant dif

191 showed a procoagulant shift with decreasing kidney function in controls, most notably factor VIII an

192 evidence has demonstrated the importance of kidney function in healthy aging.

193 atterns in early life that may be related to kidney function in later life, we examined the associati

194 d to smaller kidneys and subsequent impaired kidney function in later life.

195 of dietary phosphorus intake and the role of kidney function in managing serum phosphorus homeostasis

196 gest that eculizumab treatment may stabilize kidney function in patients with chronic persistent DSA

197 (2) or more is associated with rapid loss of kidney function in patients with eGFR of at least 60 mL/

198 inally measured fetal and infant growth with kidney function in school-aged children.

199 vel minimally invasive techniques to measure kidney function in SCID mice with adriamycin-induced nep

200 rosis, slowed cyst progression, and improved kidney function in the Arl13b mutant mouse.

201 To determine whether the acute declines in kidney function in the intensive BP lowering arm of two

202 nal pelvis and calices, resulting in loss of kidney function in the most severe cases.

203 ted cystic and fibrotic lesions and impaired kidney function in these mice, consequently leading to a

204 cedural hypoxia, increased RBF, and improved kidney function in this pilot trial.

205 markers of cardiometabolic disease risk and kidney function in US adults.

206 stem cell transplant had stable or improved kidney function, indicating the effectiveness of aggress

207 ase and of mortality in patients with normal kidney function infected with HCV are unclear.

208 for age, race, traditional CVD risk factors, kidney function, insulin resistance, MRI and dual-energy

209 rior lacunar stroke and relatively preserved kidney function, intensive BP lowering was associated wi

210 RD-related cancer incidence was lower during kidney function intervals (kidney cancer: HR, 0.8; 95% C

211 cancer registries, and compared incidence in kidney function intervals (time with a transplant) with

212 and immune-related cancer was higher during kidney function intervals than during nonfunction interv

213 Normal kidney function involves numerous different cell types,

214 Kidney function is an important aspect for patient outco

215 The best available indicator of overall kidney function is GFR, which is measured either via exo

216 e been linked to diabetes, the relation with kidney function is less clear and is underresearched.

217 multaneous assessment of excretory liver and kidney function is still an unmet need in experimental s

218 al replacement therapy modality on long-term kidney function is unknown.

219 genation, short- and long-term monitoring of kidney function is warranted, as they are at highest ris

220 w-energy shockwave therapy improves stenotic kidney function, likely in part by mechanotransduction-m

221 enal pro-inflammatory mediators and salvages kidney function long term.

222 Nonlinearity in the rate of kidney function loss, which was shown in this cohort, ma

223 identifying patients at risk of progressive kidney function loss.

224 on were associated with living alone, poorer kidney function, lower perceived side effects of cortico

225 24 h with elevated serum levels of liver and kidney function markers and extended impacts over 14 day

226 ptophan and pseudouridine as non-traditional kidney function markers.

227 athy, which cannot be diagnosed with routine kidney function markers.

228 ubular secretion as an independent marker of kidney function may provide insight into kidney disease

229 sm of these drugs in the setting of impaired kidney function may subject patients with CKD to alterat

230 wise correlation (r>/=0.50) with established kidney function measures: C-mannosyltryptophan, pseudour

231 APOL1 risk status is associated with lower kidney function, more glomerulosclerosis and interstitia

232 wed statistically significant differences in kidney function, mortality, RRT, cardiovascular events,

233 condition at baseline, remission of abnormal kidney function occurred in 86% (95% CI, 72 to 100), rem

234 Postoperative decline in kidney function occurred mainly in the first year after

235 Diuresis, a marker of improved kidney function, occurred earlier in the delayed-strateg

236 tho associated with lower odds of decline in kidney function (odds ratio, 0.78 [95% confidence interv

237 Kidney function of UAKD mice was actually deteriorated b

238 with eGFR to investigate the causal role of kidney function on CHD.

239 he impact of age, body mass index (BMI), and kidney function on the diagnostic accuracy of tryptase,

240 relationship between cTnT concentration and kidney function on the outcome of 30-day mortality in a

241 kidney disease, the impact of pre-operative kidney function on the risk of post-operative pulmonary

242 These variants may either affect kidney function or creatinine synthesis and excretion.

243 irrhotic portal hypertension who have normal kidney function or do not have severe extrahepatic condi

244 with any significant alterations in liver or kidney function or other safety concern.

245 rkalemia is common in patients with impaired kidney function or who take drugs that inhibit the renin

246 (CI): 1.104, 1.953; P = 0.008) and impaired kidney function (OR = 1.902, 95% CI: 1.054, 3.432; P = 0

247 on produced significant changes in VO2 peak, kidney function, or urine albumin-to-creatinine ratio.

248 evaluating cross-sectional associations with kidney function outcomes.

249 ween longitudinal changes in each measure of kidney function over 2 years and risks of ESRD, nonfatal

250 p between pro-ENK level and deterioration of kidney function over time.

251 ion of intact nephrons, lead to a decline in kidney function over time.

252 e for SRF and the prediction of postdonation kidney function (PDKF).

253 association between posttransplant factors (kidney function, perceived side effects of immunosuppres

254 Kidney function, perceived side effects, comorbidities,

255 Accurate assessment of kidney function plays an essential role for optimal clin

256 of the following clinical findings: reduced kidney function, proteinuria, or hematuria with other ca

257 sed kidney function, and progressive loss of kidney function; randomized controlled trials are warran

258 stable ICM and no substantial impairment of kidney function received intracoronary BMC administratio

259 to ischemic injury, as reflected by improved kidney function, reduced histologic damage, suppression

260 cted against, or reversed, podocyte loss and kidney function reduction (rise in plasma creatinine con

261 Graft survival, patient survival, kidney function, rejections, number of columns, adverse

262 between soluble klotho levels and decline in kidney function (relative decline: eGFR decline >/=30%;

263 ted with high blood pressure (BP), decreased kidney function, renal replacement therapy (RRT), and de

264 alities, leading to slow progressive loss of kidney function requiring dialysis and kidney transplant

265 ectomy cryosections from persons with normal kidney function revealed that APOL1 protein was markedly

266 In patients with ESRD, residual kidney function (RKF) contributes to achievement of adeq

267 uidelines define this condition as decreased kidney function shown by glomerular filtration rate (GFR

268 This study explores the association between kidney function, side effects of immunosuppressive treat

269 onal studies have shown that acute change in kidney function (specifically, AKI) is a strong risk fac

270 survival benefit was consistent through all kidney function strata, including dialysis patients.

271 multiple myeloma and persistent reduction in kidney function strongly affects prognosis.

272 Other intrinsic kidney functions, such as proximal tubular secretion, ty

273 sments included adverse events and liver and kidney function tests.

274 mus (EVR + rTAC) led to significantly better kidney function than standard TAC (TAC-C), without compr

275 dney injury (AKI) promotes an abrupt loss of kidney function that results in substantial morbidity an

276 tion was noted between BMI and rapid loss of kidney function that was more prominent with increasing

277 s, risk factors, and the latent variable for kidney function, the linear spline terms representing 1,

278 fit of renal-artery stenting with respect to kidney function, the usefulness of stenting for the prev

279 h nephrotic syndrome and progressive loss of kidney function, thereby encouraging prompt initiation o

280 as test beds for therapies ideally requires kidney function to be measured repeatedly in a safe, min

281 ts of trials conducted in people with normal kidney function to patients with CKD.

282 own only to regulate salt homeostasis in the kidney functions to balance T cell adhesion and migratio

283 merular filtration rate (eGFR), a measure of kidney function used to define chronic kidney disease (C

284 The median time to recovery of kidney function was 15 days with AC607 and 12 days with

285 Worsening in kidney function was associated with lower HRQoL.

286 liver function at EOP were similar, although kidney function was better with micafungin.

287 Kidney function was estimated using the abbreviated Modi

288 Kidney function was grouped into 6 categories based on p

289 Kidney function was measured by cystatin C-based estimat

290 The lowest risk for loss of kidney function was noted in patients with BMI of at lea

291 Kidney function was significantly better in group 2, if

292 donation total kidney volume and predonation kidney function was the highest for RCV (0.58 with creat

293 rin inhibitor immunosuppression and preserve kidney function, we have added belatacept to the therape

294 stological markers of insulin resistance and kidney function were measured.

295 se with rapidly progressive deterioration in kidney function, which, histologically, manifests as cre

296 a significant and an inverse association for kidney function with apoA-IV concentrations (P = 5.5 x 1

297 f delayed >48 h) is associated with improved kidney function with no DGF post-KT, and improved patien

298 ic changes on pre-LT kidney biopsy recovered kidney function within 1 month from LT.

299 creased risk of death rises exponentially as kidney function worsens and is largely attributable to d

300 I, the epithelium can regenerate and restore kidney function, yet little is known about the endotheli